This document contains links to newsletter articles about drugs covered under the medical benefit.

**The Record, December 2019**
- Certain infusion drugs won't be covered in outpatient hospitals, starting in January
- Commercial PPO members will need authorization for Eylea and Lucentis
- J0642 replaces J3490 and J3590 when billing levoleucovorin (khapzory)

**The Record, November 2019**
- Blue Cross and BCN to cover select hyaluronic acid products, starting Jan. 1

**The Record, October 2019**
- We'll cover hemophilia drugs under the pharmacy benefit for most commercial members, starting Jan. 1

**The Record, September 2019**
- Quarterly update: Requirements changed for some commercial medical benefit drugs
- Inflectra to be preferred infliximab product for adult commercial PPO members, beginning Nov. 1
- We're adding medical benefit specialty drugs to prior authorization and site of care programs for PPO members, starting Oct. 1

**The Record, August 2019**
- Immune, subcutaneous globulin dosing strategy changing

**The Record, July 2019**
- Blue Cross expanding medical benefit prior authorization program for commercial members starting Aug. 1

**The Record, May 2019**
- Medical drug prior authorization program expanding